Twist Bioscience Corp (TWST)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-13

Key Insights

  • Adam Laponis, the Chief Financial Officer of Twist Bioscience Corp, sold 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share.
  • The sale was conducted to cover tax withholding obligations in connection with the vesting of Restricted Stock Units, and was not a discretionary trade.
  • Following the reported transaction, Laponis still beneficially owns 125,694 shares of Twist Bioscience's common stock.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-02-13

Key Insights

  • The reporting person, Dennis Cho, sold 5,000 shares of Twist Bioscience Corp (TWST) stock on February 11, 2026 at an average price of $49.93 per share.
  • The sale was executed pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person, indicating it was a planned transaction.
  • Following the reported transaction, the reporting person continues to beneficially own 138,581 shares of TWST stock.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-02-13

Key Insights

  • Insider Adam Laponis, the Chief Financial Officer, sold 7,000 shares of Twist Bioscience Corp (TWST) at an average price of $50 per share.
  • The share sale was executed pursuant to a pre-planned 10b5-1 trading plan, indicating the transaction was not made on the basis of any material non-public information.
  • Laponis still holds 130,031 shares of TWST after the reported transaction, suggesting he maintains a significant ownership stake in the company.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-01-13

Key Insights

  • The reporting person, Adam Laponis, who is the Chief Financial Officer of Twist Bioscience Corp, sold 2,738 shares of the company's common stock on January 9, 2026.
  • The sale of shares was to cover tax withholding obligations in connection with the vesting of restricted stock units, and was not a discretionary trade by the reporting person.
  • Following the reported transaction, the reporting person still beneficially owns 140,031 shares of the company's common stock.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Twist Bioscience Corp filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.